Premium
Sleep complaints and their relation with drug treatment in patients suffering from Parkinson's disease
Author(s) -
GómezEsteban Juan Carlos,
Zarranz Juan Jose,
Lezcano Elena,
Velasco Fernando,
Ciordia Roberto,
Rouco Idoia,
Losada Jose,
Bilbao Iker
Publication year - 2006
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.20874
Subject(s) - parkinson's disease , nocturia , levodopa , rating scale , medicine , disease , dopaminergic , physical therapy , psychology , dopamine , developmental psychology , urinary system
The aim of this research was to quantify sleep problems in patients suffering from Parkinson's disease by means of the new Parkinson's Disease Sleep Scale (PDSS) and to correlate such problems with the possible influence of current drug treatment. A total of 70 patients (36 men and 34 women) with a diagnosis of Parkinson's disease were enrolled. Their mean age was 69.7 ± 8.2 years, and duration of disease was 7.4 ± 4.8 years. All patients completed the PDSS and the Unified Parkinson's Disease Rating Scale (UPDRS Parts I–IV). Drug consumption and doses were registered. The mean score on the PDSS scale was 109.23 ± 19.75 and on the UPDRS III scale was 25.24 ± 11.35. The lowest scores were obtained in Item 3 (sleep fragmentation): 5.53 (2.46); and in Item 8 (nocturia): 5.75 (2.91). There was a weak correlation between the PDSS and UPDRS III (cc = −0.355, P = 0.003), PDSS and UPDRS I (cc = −0.272, P = 0.02), and PDSS and UPDRS IV (cc = −0.416, P < 0.001). Motor conditions, mental state, and drug complications influence sleep quality. Although this effect was significant, it was not of a great magnitude. Dopaminergic drugs did not increase daytime sleepiness. As a whole, sleep quality in patients who took dopaminergic agonists did not differ from that of patients who took levodopa in monotherapy. © 2006 Movement Disorder Society